Evidence map›Paper›PMID 32134433›Full record

ArticleJAMA ophthalmology2020

Evolving Longitudinal Retinal Observations in a Cohort of Survivors of Ebola Virus Disease.

Paul J Steptoe, Fayiah Momorie, Alimamy D Fornah, Patrick Komba, Elizabeth Emsley, Janet T Scott, Samantha J Williams, Simon P Harding, Matthew J Vandy, Foday Sahr and 2 more

Open access · hybridAbstract read
In one paragraph

Article in JAMA ophthalmology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 6 institutions in 3 countries.

Paul J SteptoeDepartment of Women's and Children's Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, England.
Fayiah MomorieMedical Research Council, University of Glasgow Centre for Virus Research, Glasgow, Scotland.
Alimamy D FornahMedical Research Council, University of Glasgow Centre for Virus Research, Glasgow, Scotland.
Patrick KombaMedical Research Council, University of Glasgow Centre for Virus Research, Glasgow, Scotland.
Elizabeth EmsleySt Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, England.
Janet T ScottNational Institute for Health Research Health Protection Research Unit in Emerging and Zoonotic Infections, University of Liverpool, Liverpool, England.
Samantha J WilliamsDepartment of Women's and Children's Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, England.
Simon P HardingSt Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, England.
Matthew J VandyConnaught Hospital, Freetown, Sierra Leone.
Foday SahrMedical Research Council, University of Glasgow Centre for Virus Research, Glasgow, Scotland.
Nicholas A V BeareSt Paul's Eye Unit, Royal Liverpool University Hospital, Liverpool, England.
Malcolm G SempleDepartment of Women's and Children's Health, Faculty of Health and Life Sciences, University of Liverpool, Liverpool, England.
MRC University of Glasgow Centre for Virus Research · GBUniversity of Liverpool · GBHealth Protection Research Unit in Emerging and Zoonotic Infections at University of Liverpool · GBHealth & Life (Taiwan) · TWMedical Research Council · GBRoyal Liverpool University Hospital · GB

Funding

Wellcome Trust
6 · The paper itself

Abstract

Importance: The 2-year ophthalmic sequelae of Ebola virus disease (EVD) in survivors of the 2013 to 2016 epidemic is unknown and may have public health implications for future outbreaks. Objective: To assess the potential for uveitis recurrence, the behavior of dark without pressure, and visual outcomes in a cohort of Sierra Leonean survivors of EVD 2 years following the 2013 to 2016 Ebola epidemic. Design, Setting, and Participants: Prospective, 1-year observational cohort study performed between 2016 and 2017 at 34 Military Hospital, Freetown, Sierra Leone. Participants included survivors of EVD who reported ocular symptoms since Ebola treatment unit discharge and were participants of a previous case-control study. Participants were invited for ophthalmic reexamination and finger-prick blood sampling for immunoglobulin G (IgG) to Toxoplasma gondii and HIV. Exposures: Ebola virus disease. Main Outcomes and Measures: Primary outcome measure: comparative ultra-widefield retinal imaging. Secondary outcome measures: visual acuity and detection of IgG to T gondii and HIV. Results: Of 57 survivors of EVD who underwent repeated ophthalmic evaluation, 37 were women (64.9%). Mean (SD) age was 31.9 (11.1) years. Median interval between first and last examination was 370 days (interquartile range [IQR], 365-397.5 days), and median time from discharge to last examination was 779 days (IQR, 732-821 days). Fifteen eyes of 10 survivors (17.5%) had retinal lesions secondary to EVD. No new EVD-associated retinal lesions were observed. Two survivors (3.5%) developed new posterior uveitis resembling toxoplasmosis chorioretinitis and 41 (73%) were seropositive for T gondii IgG. Areas of dark without pressure were observed either confined to the perimeter of Ebola retinal lesions (n = 7) and non-Ebola lesions (n = 2), involving extensive retinal areas adjacent to Ebola retinal lesions (n = 4) and non-Ebola lesions (n = 2) or in isolation (n = 6). Both expansion and regression of areas of dark without pressure were observed over the study period. Best eye-presenting visual acuity had mild or no visual impairment in 55 survivors (96.4%) 2 years following discharge. Conclusions and Relevance: Vision was maintained in survivors of EVD 2 years following discharge. Evolving regions of dark without pressure may be associated with EVD retinal lesions and might suggest the presence of an ongoing intraretinal stimulus, which may be associated with infective etiology. Treatment strategies should account for the possibility of toxoplasmosis chorioretinitis recurrence within survivors of EVD.

Indexed as

SurvivorsAdultAntibodies, ProtozoanCase-Control StudiesChorioretinitisEbolavirusEye Infections, ParasiticEye Infections, ViralFemaleFollow-Up StudiesHemorrhagic Fever, EbolaHumansImmunoglobulin GMaleProspective StudiesRetinal DiseasesAntibodies, ProtozoanImmunoglobulin G

Identifiers

PMID32134433
PMCPMC7146102
OpenAlexW3009097116

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.